CRISPR-mediated Stxbp1 gene activation restores Munc18-1 levels in Stxbp1-haploinsufficient mice
- 1Institute of Brain Science, Nagoya City University Graduate School of Medical Sciences
Abstract
Mutations in the syntaxin-binding protein 1 (STXBP1) gene, which encodes the presynaptic protein Munc18-1, cause a spectrum of severe epileptic encephalopathies and neurodevelopmental disorders, including Ohtahara syndrome, for which no curative treatment is currently available. Because the disease pathomechanism is thought to be driven by haploinsufficiency, restoring expression of the wild-type allele to physiological levels could provide therapeutic benefit. Here, we evaluated CRISPR-mediated transcriptional activation (CRISPR-ON), based on a dCas9-VPR transcriptional activator, as a strategy to upregulate endogenous Stxbp1 expression in a Stxbp1-haploinsufficient (Stxbp1+/-) mouse model. Screening of guide RNAs (gRNAs) targeting the Stxbp1 promoter in Neuro2A cells identified a multiplexed four-gRNA cassette that elevated Stxbp1 mRNA approximately six-fold. AAV-PHP.eB vectors co-expressing this 4xgRNA cassette and Cre recombinase under the EF1a promoter were administered intracerebroventricularly to neonatal Stxbp1+/-/dCas9-VPRfl/+ mice. CRISPR-ON treatment raised brain Stxbp1 mRNA in Stxbp1+/- mice to 1.5-fold the level of wild-type controls, whereas Munc18-1 protein was restored to the wild-type level. In small exploratory cohorts, spike-wave discharge frequency and attack counts tended to be lower in CRISPR-ON-treated than in untreated Stxbp1+/- mice; the discharge data, from two animals per group, were not tested statistically, and the difference in attack counts was not significant, so efficacy cannot be judged from the present data. Locomotor activity was normal in untreated mutants and unaffected by treatment; reduced body weight was not rescued. Together, these findings establish that CRISPR-ON can correct Stxbp1/Munc18-1 expression in vivo, whereas its effect on disease phenotypes remains to be determined.
Related
- AAV-mediated TBR1 supplementation ameliorates behavioral and electrophysiological abnormalities in Tbr1-haploinsufficient mice
- Juvenile AAV-Mediated MEF2C Gene Replacement Ameliorates Selected Phenotypes in Mef2c-Haploinsufficient Mice
- Metabolite-mediated reversal of motor hyperactivity restores ciliary function
- CRISPR-based transcriptional activation deciphers strigolactone biosynthesis in Nicotiana benthamiana.
- The aminoadamantane derivative 3F2 modulates monocyte and NK cell activation and restores immune mediators altered by Monkeypox virus stimuli.
BibTeX
@misc{yamagata2026crisprmediated,
title = {{CRISPR-mediated Stxbp1 gene activation restores Munc18-1 levels in Stxbp1-haploinsufficient mice}},
author = {T. Yamagata and R. Ikebe and K. Kobayashi and N. Nagata and M. Saito and Y. Hibi and K. Yamakawa and T. Suzuki},
howpublished = {bioRxiv},
year = {2026},
month = jun,
doi = {10.64898/2026.06.08.730996},
url = {https://www.biorxiv.org/content/10.64898/2026.06.08.730996v2},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - CRISPR-mediated Stxbp1 gene activation restores Munc18-1 levels in Stxbp1-haploinsufficient mice
AU - T. Yamagata
AU - R. Ikebe
AU - K. Kobayashi
AU - N. Nagata
AU - M. Saito
AU - Y. Hibi
AU - K. Yamakawa
AU - T. Suzuki
PY - 2026
DA - 2026/06/08
PB - bioRxiv
DO - 10.64898/2026.06.08.730996
UR - https://www.biorxiv.org/content/10.64898/2026.06.08.730996v2
AB - Mutations in the syntaxin-binding protein 1 (STXBP1) gene, which encodes the presynaptic protein Munc18-1, cause a spectrum of severe epileptic encephalopathies and neurodevelopmental disorders, including Ohtahara syndrome, for which no curative treatment is currently available. Because the disease pathomechanism is thought to be driven by haploinsufficiency, restoring expression of the wild-type allele to physiological levels could provide therapeutic benefit. Here, we evaluated CRISPR-mediated transcriptional activation (CRISPR-ON), based on a dCas9-VPR transcriptional activator, as a strategy to upregulate endogenous Stxbp1 expression in a Stxbp1-haploinsufficient (Stxbp1+/-) mouse model. Screening of guide RNAs (gRNAs) targeting the Stxbp1 promoter in Neuro2A cells identified a multiplexed four-gRNA cassette that elevated Stxbp1 mRNA approximately six-fold. AAV-PHP.eB vectors co-expressing this 4xgRNA cassette and Cre recombinase under the EF1a promoter were administered intracerebroventricularly to neonatal Stxbp1+/-/dCas9-VPRfl/+ mice. CRISPR-ON treatment raised brain Stxbp1 mRNA in Stxbp1+/- mice to 1.5-fold the level of wild-type controls, whereas Munc18-1 protein was restored to the wild-type level. In small exploratory cohorts, spike-wave discharge frequency and attack counts tended to be lower in CRISPR-ON-treated than in untreated Stxbp1+/- mice; the discharge data, from two animals per group, were not tested statistically, and the difference in attack counts was not significant, so efficacy cannot be judged from the present data. Locomotor activity was normal in untreated mutants and unaffected by treatment; reduced body weight was not rescued. Together, these findings establish that CRISPR-ON can correct Stxbp1/Munc18-1 expression in vivo, whereas its effect on disease phenotypes remains to be determined.
ER -